Michael York - Metacrine Chief Officer
| MTCRDelisted Stock | USD 0.49 0.00 0.00% |
Insider
Michael York is Chief Officer of Metacrine
| Age | 58 |
| Phone | 858 369 7800 |
| Web | https://www.metacrine.com |
Michael York Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael York against Metacrine stock is an integral part of due diligence when investing in Metacrine. Michael York insider activity provides valuable insight into whether Metacrine is net buyers or sellers over its current business cycle. Note, Metacrine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Metacrine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael York over a year ago Sale by Michael York of 107054 shares of MetacrineInc |
Metacrine Management Efficiency
The company has return on total asset (ROA) of (0.3686) % which means that it has lost $0.3686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9072) %, meaning that it created substantial loss on money invested by shareholders. Metacrine's management efficiency ratios could be used to measure how well Metacrine manages its routine affairs as well as how well it operates its assets and liabilities.Metacrine currently holds 13.3 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Metacrine has a current ratio of 21.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Metacrine's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Gary Hattersley | Nuvation Bio | 57 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| W Vernon | Nuvation Bio | 65 | |
| Maurice Zauderer | Vaccinex | 78 | |
| Elizabeth Nguyen | Surrozen | N/A | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Michelle Doig | Nuvation Bio | 46 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Christopher Garcia | Surrozen | N/A | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| MS JD | Surrozen | 62 | |
| Roeland Nusse | Surrozen | 74 | |
| David Hanley | Nuvation Bio | 54 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| Calvin MD | Surrozen | N/A | |
| AO FRACP | Assembly Biosciences | 65 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Uri MD | Assembly Biosciences | 52 | |
Management Performance
| Return On Equity | -0.91 | |||
| Return On Asset | -0.37 |
Metacrine Leadership Team
Elected by the shareholders, the Metacrine's board of directors comprises two types of representatives: Metacrine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Metacrine. The board's role is to monitor Metacrine's management team and ensure that shareholders' interests are well served. Metacrine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Metacrine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Millican, Chief Officer | ||
| Theresa Lowry, VP HR | ||
| Michael York, Chief Officer | ||
| MHS MD, CEO Pres |
Metacrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Metacrine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | |||
| Return On Asset | -0.37 | |||
| Current Valuation | (23.98 M) | |||
| Shares Outstanding | 42.57 M | |||
| Shares Owned By Insiders | 12.29 % | |||
| Shares Owned By Institutions | 35.96 % | |||
| Number Of Shares Shorted | 87.42 K | |||
| Price To Book | 0.40 X | |||
| Gross Profit | (45.47 M) | |||
| EBITDA | (60.71 M) |
Pair Trading with Metacrine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Metacrine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Metacrine will appreciate offsetting losses from the drop in the long position's value.Moving against Metacrine Stock
| 0.56 | AKO-B | Embotelladora Andina | PairCorr |
| 0.53 | CMXHF | CSL Limited | PairCorr |
| 0.46 | CSLLY | CSL | PairCorr |
| 0.46 | AULT | Ault Alliance Symbol Change | PairCorr |
| 0.35 | REGN | Regeneron Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Metacrine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Metacrine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Metacrine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Metacrine to buy it.
The correlation of Metacrine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Metacrine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Metacrine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Metacrine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Metacrine Stock
If you are still planning to invest in Metacrine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metacrine's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |